10 withdrawn. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Withdrawn 10 |
| Phase 1 | 2 | Withdrawn 2 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis Placebo, Nipocalimab, Standard-of-care treatment - Lupus Nephritis | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2026-01-15 | 2026-02-27 | |
| A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) IMPT-514 - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Withdrawn | Lyell Immunopharma, Inc. | 2024-02-15 | 2025-02-10 | |
| Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis Mycophenolate Mofetil - Lupus Nephritis | Phase 2 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2023-07-01 | 2023-08-30 | |
| Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome ADX-629 - Nephrotic Syndrome | Phase 2 | Withdrawn | Aldeyra Therapeutics, Inc. | 2023-01-01 | 2024-04-17 | |
| Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy SM101, Placebo - Immunoglobulin A Nephropathy | Phase 2 | Withdrawn | Baxalta now part of Shire | 2015-12-31 | 2022-02-07 | |
| Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg - IGA Nephropathy | Phase 2 | Withdrawn | Rigel Pharmaceuticals | 2015-09-01 | 2015-10-23 | |
| Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Belimumab 10 mg, Placebo - Glomerulonephritis, Membranous | Phase 2 | Withdrawn | GlaxoSmithKline | 2013-04-01 | 2017-03-22 | |
| Rituximab Treatment of Focal Segmental Glomerulosclerosis rituximab - Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 | Withdrawn | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2008-01-01 | 2025-05-06 | |
| Study of LJP 394 (Abetimus Sodium) in Lupus Patients abetimus sodium (LJP 394) - Systemic Lupus Erythematosus | Phase 2 | Withdrawn | La Jolla Pharmaceutical Company | 2006-09-01 | 2015-09-01 |
Lupus Nephritis (5) · Lupus Erythematosus, Systemic (3) · Glomerulonephritis, IGA (2) · Glomerulosclerosis, Focal Segmental (2) · Proteinuria (2) · Glomerulonephritis, Membranous (1) · Nephritis (1) · Nephrosis, Lipoid (1) · Nephrotic Syndrome (1) · Renal Insufficiency, Chronic (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Kidney Diseases (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Nephritis (9) · Autoimmune Diseases (8) · Immune System Diseases (8) · Connective Tissue Diseases (5) · Skin and Connective Tissue Diseases (5) · Pathological Conditions, Signs and Symptoms (3) · Lupus Erythematosus, Systemic (2) · Signs and Symptoms (2)
ADX-629 (1) · Mycophenolic Acid (1) · Rituximab (1) · abetimus (1) · belimumab (1) · fostamatinib (1)
AbelZeta Inc. (1) · Aldeyra Therapeutics, Inc. (1) · Baxalta now part of Shire (1) · Children's Hospital Medical Center, Cincinnati (1) · GlaxoSmithKline (1) · Janssen Research & Development, LLC (1) · La Jolla Pharmaceutical Company (1) · Lyell Immunopharma, Inc. (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Rigel Pharmaceuticals (1)
United States (6) · Australia (2) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Mark D Pescovitz, MD (1) · Matthew D Linnik, PhD (1) · Scott Antonia (1)
PMID 34778952, PMID 38724717, PMID 39513526
2015 (1), R21DK077329 (1)